HK1021388A1 - Ob fusion protein compositions and methods - Google Patents

Ob fusion protein compositions and methods

Info

Publication number
HK1021388A1
HK1021388A1 HK99105565A HK99105565A HK1021388A1 HK 1021388 A1 HK1021388 A1 HK 1021388A1 HK 99105565 A HK99105565 A HK 99105565A HK 99105565 A HK99105565 A HK 99105565A HK 1021388 A1 HK1021388 A1 HK 1021388A1
Authority
HK
Hong Kong
Prior art keywords
methods
fusion protein
protein compositions
compositions
fusion
Prior art date
Application number
HK99105565A
Other languages
English (en)
Inventor
Michael Benjamin Mann
Randy Ira Hecht
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of HK1021388A1 publication Critical patent/HK1021388A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
HK99105565A 1996-12-20 1999-11-30 Ob fusion protein compositions and methods HK1021388A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77097396A 1996-12-20 1996-12-20
PCT/US1997/023183 WO1998028427A1 (en) 1996-12-20 1997-12-11 Ob fusion protein compositions and methods

Publications (1)

Publication Number Publication Date
HK1021388A1 true HK1021388A1 (en) 2000-06-09

Family

ID=25090296

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99105565A HK1021388A1 (en) 1996-12-20 1999-11-30 Ob fusion protein compositions and methods

Country Status (26)

Country Link
EP (2) EP0954588B1 (xx)
JP (2) JP4175668B2 (xx)
KR (1) KR100937550B1 (xx)
CN (1) CN1195858C (xx)
AR (2) AR009436A1 (xx)
AT (1) ATE351910T1 (xx)
AU (1) AU5606098A (xx)
BG (1) BG64288B1 (xx)
BR (1) BR9713755A (xx)
CA (1) CA2275183A1 (xx)
CZ (1) CZ298203B6 (xx)
DE (1) DE69737266T2 (xx)
DK (1) DK0954588T3 (xx)
EA (2) EA004790B1 (xx)
ES (1) ES2280083T3 (xx)
HK (1) HK1021388A1 (xx)
HU (1) HU227088B1 (xx)
IL (1) IL130396A (xx)
NO (2) NO324506B1 (xx)
NZ (1) NZ514145A (xx)
PL (1) PL194159B1 (xx)
PT (1) PT954588E (xx)
RS (1) RS49927B (xx)
SK (1) SK287578B6 (xx)
WO (1) WO1998028427A1 (xx)
ZA (1) ZA9711239B (xx)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2358862A1 (en) * 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
ES2183351T3 (es) * 1997-04-17 2003-03-16 Amgen Inc Composicones que comprenden conjugados de proteina ob humana activa estable con una cadena fc de inmunoglobulinas y metodos.
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
CA2321026A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
MEP42108A (en) 1998-10-23 2011-02-10 Kiren Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CA2407086A1 (en) * 2000-04-21 2001-11-01 Amgen, Inc. Integrin/adhesion antagonists
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
CN100404673C (zh) 2001-02-19 2008-07-23 默克专利有限公司 鉴定t细胞表位的方法及制备具有降低的免疫原性的分子的用途
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
JP2002306163A (ja) * 2001-04-11 2002-10-22 Chemo Sero Therapeut Res Inst 大腸菌を宿主とする遺伝子組換えヒトトロンビンの調製方法
WO2003034996A2 (en) 2001-10-22 2003-05-01 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
JP3936673B2 (ja) * 2003-06-02 2007-06-27 国立大学法人群馬大学 Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体
EA011859B9 (ru) 2004-01-05 2013-07-30 Емд Лексиген Ресерч Сентер Корп. Соединения для адресной доставки препарата к ткани или органу-мишени
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2005077094A2 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
EP1773400A2 (en) 2004-07-08 2007-04-18 Amgen Inc. Therapeutic peptides
EP1773884B1 (en) 2004-08-03 2012-03-07 Innate Pharma Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor
EP1814590B2 (en) 2004-11-01 2013-12-11 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
CN101296942A (zh) * 2005-08-11 2008-10-29 安米林药品公司 具有可选择特性的杂合多肽
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
BRPI0617688A2 (pt) 2005-10-21 2011-06-07 Hoffmann La Roche método para expressão recombinante de um polipeptìdeo
AR059193A1 (es) 2006-01-31 2008-03-12 Bayer Schering Pharma Ag Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
CA2759333A1 (en) 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
CA2768965C (en) 2009-08-14 2019-06-04 George N. Pavlakis Use of il-15 to increase thymic output and to treat lymphopenia
WO2012050925A2 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Highly soluble leptins
WO2013009539A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
EP2764565B1 (en) 2011-10-05 2023-02-22 OneD Material, Inc. Silicon nanostructure active materials for lithium ion batteries and processes, compositions, components, and devices related thereto
RS58010B1 (sr) 2012-09-27 2019-02-28 Childrens Medical Ct Corp Jedinjenja za lečenje gojaznosti i postupci za njihovu upotrebu
AU2014354831B2 (en) 2013-11-26 2017-10-26 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CA3036551A1 (en) 2016-09-12 2018-03-15 Aegerion Pharmaceuticals, Inc. Methods of detecting anti-leptin neutralizing antibodies
CN110183530A (zh) * 2019-06-21 2019-08-30 深圳市亚辉龙生物科技股份有限公司 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用
CN112618698B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白的注射制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CA2196200A1 (en) * 1994-07-29 1996-02-15 Michael Joseph Browne Novel compounds
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JPH0870875A (ja) * 1994-09-05 1996-03-19 Tosoh Corp 組換えアルカリフォスファタ−ゼ融合タンパク質
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
CA2358862A1 (en) * 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
RU2178307C2 (ru) * 1995-12-27 2002-01-20 Джинентех Инк. Производные ов-протеина

Also Published As

Publication number Publication date
EA004790B1 (ru) 2004-08-26
CN1195858C (zh) 2005-04-06
AR009436A1 (es) 2000-04-12
SK287578B6 (sk) 2011-03-04
CN1246154A (zh) 2000-03-01
DK0954588T3 (da) 2007-05-14
EP0954588A1 (en) 1999-11-10
HUP0000302A3 (en) 2005-12-28
NO20071415L (no) 1999-08-19
RS49927B (sr) 2008-09-29
NZ514145A (en) 2003-08-29
ES2280083T3 (es) 2007-09-01
BG64288B1 (bg) 2004-08-31
EP0954588B1 (en) 2007-01-17
IL130396A (en) 2011-09-27
JP4659068B2 (ja) 2011-03-30
EP1835030A1 (en) 2007-09-19
WO1998028427A1 (en) 1998-07-02
EA199900575A1 (ru) 2000-02-28
AU5606098A (en) 1998-07-17
EA200100216A1 (ru) 2001-08-27
NO324506B1 (no) 2007-11-05
JP4175668B2 (ja) 2008-11-05
YU27999A (sh) 2000-10-30
KR100937550B1 (ko) 2010-01-19
DE69737266T2 (de) 2007-11-08
KR20000069617A (ko) 2000-11-25
SK77499A3 (en) 2001-04-09
BG103522A (en) 2000-03-31
IL130396A0 (en) 2000-06-01
ZA9711239B (en) 1998-06-23
CZ9902036A3 (cs) 2000-10-11
PT954588E (pt) 2007-03-30
PL334242A1 (en) 2000-02-14
NO992779D0 (no) 1999-06-08
ATE351910T1 (de) 2007-02-15
DE69737266D1 (de) 2007-03-08
HUP0000302A2 (hu) 2000-06-28
HU227088B1 (en) 2010-06-28
BR9713755A (pt) 2000-02-01
PL194159B1 (pl) 2007-05-31
CZ298203B6 (cs) 2007-07-18
NO992779L (no) 1999-08-19
JP2001512417A (ja) 2001-08-21
AR059907A2 (es) 2008-05-07
EA004791B1 (ru) 2004-08-26
NO325096B1 (no) 2008-02-04
JP2008289487A (ja) 2008-12-04
CA2275183A1 (en) 1998-07-02

Similar Documents

Publication Publication Date Title
IL130396A0 (en) OB fusion protein compositions and methods
ZA964733B (en) Ob protein compositions and methods
HUP0200414A2 (en) Interferon-betha fusion proteins and uses
GB9616411D0 (en) Shampoo compositions and method
GB9718609D0 (en) Fusion protein
HUP0100535A3 (en) Hydrophobically-modified protein compositions and methods
ZA989399B (en) Method and composition
GB9608130D0 (en) Adam proteins and uses thereof
ZA9710338B (en) Proteins
GB9624501D0 (en) Insecticial compositions and method
GB9614033D0 (en) Modified protein G and fragments thereof
AU3923000A (en) Agp-1 fusion protein compositions and methods
HUP0000280A3 (en) Canine ob protein compositions and methods
GB2318356B (en) Composition and method
GB9423372D0 (en) Proteins and their uses
GB9620286D0 (en) Composition comprising protein fibres
SI0877803T1 (sl) Receptor ob-proteina in sorodni sestavki in postopki
GB9604865D0 (en) Modified proteins
AU1902999A (en) Hydrophobically-modified protein compositions and methods
GB9624028D0 (en) Modified proteins
GB9614293D0 (en) Modified proteins
GB9611896D0 (en) Modified proteins
GB9828306D0 (en) Modified protein G and fragments thereof
GB9704297D0 (en) Composition and method
ZA989401B (en) Method and composition

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20121211